Cannabis Stocks Directory

AFC Gamma, Inc. - (NASDAQ: AFCG)
AFC Gamma, a commercial mortgage REIT, provides $10-100 million loans to state-licensed cannabis operators in the U.S. In 2025, it expands its 14-loan portfolio across 15 states, leveraging U.S. rescheduling to reduce banking barriers. Its diversified lending model positions AFC Gamma to capitalize on the $57 billion U.S. cannabis market, offering stable returns despite industry volatility.

AdvisorShares Pure US Cannabis ETF - (NYSEARCA: YOLO)
The AdvisorShares Pure US Cannabis ETF tracks U.S.-focused cannabis companies, with top holdings like Curaleaf and Green Thumb. In 2025, with a 0.76% expense ratio, it benefits from Schedule III rescheduling, boosting investor interest. Its focus on cultivators and retailers positions YOLO to capture growth in the $57 billion U.S. market, offering diversified exposure.

Alliance Growers Corp. - (CSE: ACG), (OTCQB: ALGWF)
Alliance Growers develops cannabis production and distribution through its Four Pillars strategy, focusing on cultivation and branding. In 2025, it leverages Canada's recreational market and U.S. rescheduling for export potential. Note: Verify trading status due to low liquidity. Its partnerships position Alliance to tap into the $200 billion global cannabis market, despite small-cap risks.

Amplify Alternative Harvest ETF - (NYSEARCA: MJ)
The Amplify Alternative Harvest ETF tracks global cannabis companies, with holdings like Tilray and Innovative Industrial Properties. In 2025, with a 0.75% expense ratio, it capitalizes on U.S. rescheduling and EU medical cannabis growth. Its diversified portfolio positions MJ to benefit from the $200 billion global market, appealing to investors seeking broad exposure.

American Cannabis Company, Inc. - (OTC: AMMJ)
American Cannabis Company offers consulting and cultivation solutions, including its "Her Highness" brand for female consumers. In 2025, it expands in Colorado, leveraging U.S. rescheduling to enhance licensing services. Its American Cultivator Company supports growers with equipment, positioning AMMJ to capitalize on the $57 billion U.S. market, despite penny stock volatility.

American Green, Inc. - (OTC: ERBB)
American Green, a pioneer since 2009, focuses on cannabis cultivation, retail, and smart vending systems. In 2025, it expands branded products and vending solutions, leveraging U.S. rescheduling. With over 50,000 shareholders, its cultivation partnerships position it for the $200 billion global market, though penny stock risks persist.

Aurora Cannabis Inc. - (NASDAQ: ACB), (TSX: ACB.TO)
Aurora Cannabis, a global producer, focuses on medical and recreational cannabis in Canada and Europe. In 2025, it leverages a $5.97 stock surge (web ID: 1) and Q2 2025 results to expand EU medical sales. Its Whistler Medical Marijuana acquisition enhances premium offerings, positioning Aurora for the $200 billion market.

Auxly Cannabis Group Inc. - (TSX: XLY.TO), (OTCQB: CBWTF)
Auxly Cannabis holds a 5% Canadian market share, producing premium vape and pre-roll products. In 2025, it leverages a 34% gross margin and $123.4 million debt conversion by Imperial Brands to expand. Auxly's innovative formats position it for Canada's recreational market and U.S. rescheduling growth.

Body and Mind Inc. - (CSE: BAMM)
Body and Mind cultivates and retails cannabis from its 20,000 sq. ft. Nevada facility. In 2025, it expands U.S. dispensaries, leveraging Schedule III rescheduling for medical cannabis access. Its focus on quality extracts positions it to meet demand in the $57 billion U.S. market, despite small-cap volatility.

Botanix Pharmaceuticals Ltd. - (ASX: BOT.AX)
Botanix Pharmaceuticals develops cannabinoid-based treatments for skin conditions like acne. In 2025, it advances clinical trials, leveraging U.S. rescheduling to expand medical applications. Its pharmaceutical-grade products position Botanix to tap into the $200 billion global cannabis market, offering a unique medical sector play.

Canopy Growth Corporation - (TSX: WEED.TO), (NASDAQ: CGC)
Canopy Growth, a global leader, produces diversified cannabis products. In 2025, it leverages a 16.14% stock surge (web ID: 14) and Q2 2025 results to expand EU and U.S. medical cannabis via its $229 million Hexo acquisition. Canopy's scale positions it for the $57 billion U.S. market.

The Cannabist Company Holdings Inc. - (CBOE CA: CBST), (OTCQX: CBSTF)
The Cannabist Company operates 125 U.S. dispensaries and cultivation facilities. In 2025, despite a 79% stock drop, its low price-to-sales ratio and revenue growth position it for upside post-rescheduling. Brands like Seed & Strain target the $57 billion U.S. market, balancing growth with regulatory risks.

Chicago Atlantic Real Estate Finance, Inc. - (NASDAQ: REFI)
Chicago Atlantic, a commercial mortgage REIT, provides loans to U.S. cannabis operators, addressing banking constraints. In 2025, it expands its portfolio post-rescheduling, reducing IRS 280E tax burdens. Its focus on institutional lending positions REFI for stable returns in the $57 billion U.S. market.

Cresco Labs Inc. - (CSE: CL), (OTCQX: CRLBF)
Cresco Labs manages 70 U.S. dispensaries across 10 states. In 2025, it leverages Schedule III rescheduling to expand medical cannabis, targeting $1.3 billion in revenue. Its quality focus positions Cresco to capture share in the $57 billion U.S. market, despite regulatory hurdles.

Cronos Group Inc. - (NASDAQ: CRON), (TSX: CRON.TO)
Cronos Group, backed by Altria's $1.8 billion stake, invests in brands like PEACE NATURALS. In 2025, it expands its portfolio, leveraging U.S. rescheduling for medical cannabis sales. Despite SEC fraud allegations (web ID: 16), Cronos' diversification positions it for the $200 billion global market.

Curaleaf Holdings, Inc. - (TSX: CURA), (OTCQX: CURLF)
Curaleaf, the largest U.S. cannabis company by revenue ($1.3 billion), operates 150+ dispensaries. In 2025, a 44% stock jump post-HHS rescheduling (web ID: 24) fuels medical and recreational expansion. Curaleaf's scale positions it to dominate the $57 billion U.S. market, despite valuation risks.

Delta 9 Cannabis Inc. - (TSX: DN.TO), (OTC: DLTNF)
Delta 9 operates a 95,000 sq. ft. facility in Winnipeg, producing cannabis and grow pods. In 2025, a 70% stock surge (web ID: 17) reflects penny stock momentum. Delta 9's retail and wholesale channels position it for Canada's recreational market and U.S. rescheduling, despite volatility.

Green Thumb Industries Inc. - (CSE: GTII), (OTCQX: GTBIF)
Green Thumb operates 90 U.S. dispensaries, generating $194.4 million in Q1 2021 revenue. In 2025, it expands into Virginia, leveraging rescheduling for medical cannabis growth. Its innovation focus positions Green Thumb to capture share in the $57 billion U.S. market, balancing regulatory risks.

IM Cannabis Corp. - (CSE: IMCC), (NASDAQ: IMCC)
IM Cannabis focuses on medical cannabis in Israel and Germany, exiting Canada. In 2025, a 31% stock surge (web ID: 10) and Q1 2024 results drive EU expansion. IMC's data-driven approach positions it for growth in Europe's medical cannabis market, despite small-cap volatility.

Innovative Industrial Properties, Inc. - (NYSE: IIPR)
Innovative Industrial Properties, a REIT, leases properties to U.S. cannabis operators, with a $6.81 billion market cap. In 2025, it expands its portfolio post-rescheduling, reducing banking barriers. Its stable dividends position IIPR as a low-risk play in the $57 billion U.S. market.

Jazz Pharmaceuticals plc - (NASDAQ: JAZZ)
Jazz Pharmaceuticals develops cannabinoid-based medicines, including Epidiolex for epilepsy, via its $6.7 billion GW Pharmaceuticals acquisition. In 2025, it leverages U.S. rescheduling to expand medical applications, targeting neurological disorders. Jazz's pharmaceutical focus positions it for growth in the $200 billion global cannabis market.

National Access Cannabis - (TSXV: NAC.V)
National Access Cannabis operates care centers and retail stores in Canada, providing access to licensed producers. In 2025, it explores U.S. opportunities post-rescheduling, focusing on patient education. Note: Verify trading status due to low liquidity. Its network positions NAC for Canada's market and global growth.

OrganiGram Holdings Inc. - (NASDAQ: OGI), (TSX: OGI.TO)
OrganiGram, a Canadian producer, offers cannabis products with a 2020 Canndoc Ltd. deal. In 2025, it expands multi-province facilities, leveraging U.S. rescheduling for exports. OrganiGram's quality focus positions it for growth in the $200 billion global market, despite competitive pressures.

SinglePoint, Inc. - (OTC: SING)
SinglePoint acquires cannabis-related companies, offering mobile payments and CBD via SingleSeed. In 2025, it leverages U.S. rescheduling to expand blockchain-integrated dispensary solutions. Its diversified portfolio positions SinglePoint for the $57 billion U.S. market, though penny stock volatility remains a concern.

SNDL Inc. - (NASDAQ: SNDL)
SNDL, a Canadian retailer and producer, operates 180+ stores. In 2025, it leverages 2022 restructuring to expand recreational sales, targeting U.S. entry post-rescheduling. SNDL's scale positions it for Canada's market and the $200 billion global industry, balancing growth with regulatory risks.

SpeakEasy Cannabis Club Ltd. - (CSE: EASY)
SpeakEasy Cannabis produces premium cannabis on a 290-acre British Columbia facility. In 2025, it leverages Canada's recreational market and U.S. rescheduling for exports. Its legacy growing expertise positions SpeakEasy to meet demand in the $200 billion global market, despite competition.

TerrAscend Corp. - (CSE: TSND), (OTCQX: TRSSF)
TerrAscend operates 30 U.S. dispensaries with brands like The Apothecarium. In 2025, its $10.3 million Ohio acquisition (web ID: 16) and rescheduling drive medical cannabis expansion, targeting $1 billion in revenue. TerrAscend's operations position it for the $57 billion U.S. market.

Tilray Brands, Inc. - (NASDAQ: TLRY), (TSX: TLRY.TO)
Tilray, the largest cannabis company post-Aphria acquisition, operates globally. In 2025, its $229 million Hexo acquisition and U.S. rescheduling drive EU and U.S. expansion, targeting a $100 billion opportunity (web ID: 16). Tilray's scale positions it to lead the $200 billion market.

Trulieve Cannabis Corp. - (CSE: TRUL), (OTCQX: TCNNF)
Trulieve manages 190 U.S. dispensaries, primarily in Florida. In 2025, it leverages Schedule III rescheduling for medical cannabis, targeting $1.4 billion in revenue. Its patient access focus positions Trulieve to dominate the $57 billion U.S. market, despite state-level risks.

Verano Holdings Corp. - (CSE: VRNO), (OTCQX: VRNOF)
Verano operates 140 U.S. dispensaries with premium brands. In 2025, it leverages rescheduling to expand sales, targeting $1.2 billion in revenue. Its vertical integration positions Verano to capture share in the $57 billion U.S. market, navigating regulatory uncertainties effectively.

Village Farms International, Inc. - (NASDAQ: VFF)
Village Farms, a low-cost greenhouse producer, exports medical cannabis from Canada to Germany, the U.K., and Australia. In 2025, its Q3 2024 sales doubled, leveraging rescheduling for U.S. entry. Its global focus positions Village Farms for the $200 billion market, balancing agricultural expertise with cannabis growth.

22nd Century Group Inc. - (NASDAQ: XXII)
22nd Century Group uses biotechnology to modify cannabinoid levels in cannabis plants. In 2025, it leverages U.S. rescheduling to expand medical applications, targeting pharmaceutical markets. Its innovative approach positions 22nd Century for the $200 billion global market, though it faces R&D risks.

Marijuana News